Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


User Fee “Reverse Trigger” Added To House FDA Reform Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Additional fees for postmarketing activity would not be assessed if funds were appropriated from general revenue.

You may also be interested in...

Limits On Pediatric Exclusivity And DTC Advertising Stripped From FDA Bill During Subcommittee Markup

Full Committee Chairman Dingell joins many Democrats in voting to establish civil fines and a pre-submission requirement for TV ads instead of the potential three-year moratorium set out in the draft bill.

BIO Helps Launch Coalition To Increase FDA Funding, Reduce User Fees Reliance

The Coalition for a Stronger FDA will lobby the administration before shifting its focus to congressional appropriators.

Generic Association CEO Davis Jumps To Wholesalers Group

Association for Accessible Medicines’ interim leader is General Counsel Jeffrey Francer; Chip Davis’ four-and-half year tenure included a total rebrand of the association, a significant legislative victory with the CREATES act – and an abrupt departure for the Healthcare Distribution Alliance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts